Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib and Surufatinib in Platinum-resistant Ovarian Cancer
NCT05494580Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pamiparib, surufatinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Sun Yat-sen University. Started Sep 2022; status: completed.
02
Drugs
pamiparibsurufatinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05494580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494580.